EUVIMEDEUVIMED entdecken
Crossref

Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 ‍mg

Tadayoshi Mikami, Yukari Fujiwara, Mizuki Akahori, Naoko Tomimatsu, Yuko Tamaki

Folia Pharmacologica Japonica · 2024

DOI: 10.1254/fpj.24018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Pharmacologica Japonica, 2024. Verfasst von Tadayoshi Mikami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma K.K., Development Japan. Hauptthemen laut MEDLINE: Cholesterol, LDL, RNA, Small Interfering, Proprotein Convertase 9. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inclisiran sodium (Brand name: LEQVIO® for s.c. injection syringe 300 ‍mg, hereinafter referred to as inclisiran), a small interfering ribonucleic acid (siRNA) product that targets the mRNA that encodes the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein was approved on September 25, 2023 for the indication of "Familial hypercholesterolemia, hypercholesterolemia" in Japan. Inclisiran is conjugated on the sense strand with triantennary N-acetylgalactosamine to facilitate uptake by hepatocytes. In vitro and in vivo pharmacology studies demonstrated the lowering effects of PCSK9 and LDL-C in hepatocytes and cynomolgus monkeys. It was considered unlikely to cause clinically significant risks due to toxicities arising from complementary binding to non-target RNA sequences (hybridization-dependent off-target effects). Clinical trials conducted globally including Japan in patients with familial hypercholesterolemia and hypercholesterolemia who did not reach the LDL-C target showed that inclisiran sodium 300 ‍mg dosed at Day 1, Day 90 and then every 6 months demonstrated significant LDL-C reduction and the efficacy sustained long. The majority of patients achieved the guideline recommended LDL-C targets. Inclisiran sodium 300 ‍mg was well tolerated and there were no specific safety concerns. Therefore, inclisiran is expected to be a new therapeutic option for the patients with familial hypercholesterolemia and hypercholesterolemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLRNA, Small InterferingProprotein Convertase 9HumansAnimalsHypercholesterolemiaHyperlipoproteinemia Type II

Substanzen

Cholesterol, LDLRNA, Small InterferingProprotein Convertase 9ALN-PCSPCSK9 protein, human

Autor:innen und Institutionen

  • Novartis Pharma K.K., Development Japan.

Zitieren

APA

Mikami, T., Fujiwara, Y., Akahori, M., Tomimatsu, N., & Tamaki, Y. (2024). Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 ‍mg. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.24018

Vancouver

Mikami T, Fujiwara Y, Akahori M, Tomimatsu N, Tamaki Y. Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 ‍mg. Folia Pharmacologica Japonica. 2024. doi:10.1254/fpj.24018

BibTeX
@article{Mikami2024,
  author = {Mikami, Tadayoshi and Fujiwara, Yukari and Akahori, Mizuki and Tomimatsu, Naoko and Tamaki, Yuko},
  title = {Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 ‍mg},
  journal = {Folia Pharmacologica Japonica},
  year = {2024},
  doi = {10.1254/fpj.24018}
}
Kostenlos starten →